Opendata, web and dolomites

CONQR SIGNED

Translation and Commercialization of a QSOX1-inhibitory Antibody Targeting the Tumor Microenvironment in Breast Cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CONQR project word cloud

Explore the words cloud of the CONQR project. It provides you a very rough idea of what is the project "CONQR" about.

benefit    lung    plan    relapse    stiffening    cancer    market    gene    societal    standard    experiments    chemotherapy    enzyme    conqr    preclinical    monoclonal    global    explore    physical    licensing    intended    oncology    recommended    qsox1    metastases    commercialization    therapies    matrix    revolutionizing    women    model    treatment    discoveries    made    deaths    families    negative    90    demand    outcome    brca1    found    extracellular    regimen    penetration    secreted    young    continuing    tnbc    cell    chemotherapies    entering    promise    aggressive    primary    inhibition    applicable    triple    stress    majority    radiation    significantly    antibody    adhesion    counteracts    therapeutics    reduce    perform    patient    inhibitory    showed    ecm    indications    inhibitor    mothers    metastasis    risk    imposes    breast    tumor    drug    oophorectomy    mice    therapeutic    unquantifiable    migration    preventive    efficacy    mutations    remodeling    prevents    pancreatic    reagent    added    psychological    mastectomy    agent    discovery    cancers    position    worldwide    points    adenocarcinomas   

Project "CONQR" data sheet

The following table provides information about the project.

Coordinator
WEIZMANN INSTITUTE OF SCIENCE 

Organization address
address: HERZL STREET 234
city: REHOVOT
postcode: 7610001
website: www.weizmann.ac.il

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 149˙998 €
 EC max contribution 149˙998 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-PoC
 Funding Scheme ERC-POC
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2020-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    WEIZMANN INSTITUTE OF SCIENCE IL (REHOVOT) coordinator 149˙998.00

Map

 Project objective

The high number of cancer cases worldwide points to the large global demand for therapeutics for adenocarcinomas (the majority of lung, breast, and pancreatic cancers). Cancer metastases cause more than 90% of cancer patient deaths. There is thus great need to develop more targeted cancer therapies, as well as therapies that enhance the delivery and penetration of chemotherapies to reduce side effects and increase efficacy. A specific societal need is improved therapies for triple-negative breast cancer (TNBC), to which the targeted therapies developed for other breast cancers are not applicable. TNBC treatment, particularly for women with BRCA1 gene mutations, typically involves aggressive chemotherapy, mastectomy, and radiation treatment, with preventive oophorectomy also recommended. The physical and psychological impact of this regimen on young mothers and their families is unquantifiable, and the risk of relapse imposes continuing psychological stress.

We have made a revolutionizing discovery that significantly controlled cancer cell adhesion, cell migration, primary tumor growth, and metastasis. We found that inhibition of the secreted enzyme QSOX1 by a monoclonal antibody inhibitor counteracts extracellular matrix ECM matrix stiffening and prevents tumor cell adhesion and migration. The QSOX1 inhibitor showed an added benefit in controlling primary tumor growth and metastasis when provided together with standard chemotherapy in a TNBC model in mice. The antibody drug we are developing based on these exciting discoveries has great promise for commercialization as a new therapeutic agent for TNBC and for other oncology indications.

The goal of the CONQR project is to perform key preclinical experiments and explore market entering opportunities for commercialization of a novel QSOX1-inhibitory reagent against ECM remodeling in cancer. The intended outcome will be a development and commercialization plan to best position the product for out-licensing.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CONQR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CONQR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

TroyCAN (2020)

Redefining the esophageal stem cell niche – towards targeting of squamous cell carcinoma

Read More  

InsideChromatin (2019)

Towards Realistic Modelling of Nucleosome Organization Inside Functional Chromatin Domains

Read More  

SuperH (2019)

Discovery and Characterization of Hydrogen-Based High-Temperature Superconductors

Read More